Rate Professor Darren Kelly

Professional Summary: Professor Darren Kelly

Professor Darren Kelly is a distinguished academic and researcher at the University of Melbourne, Australia, with a significant focus on biomedical sciences and translational research. Renowned for his contributions to the field of fibrosis and chronic disease, he has built a remarkable career bridging academic research with clinical and commercial applications.

Academic Background and Degrees

Professor Kelly holds advanced degrees in biomedical sciences, with a strong foundation in physiology and pharmacology. His academic journey includes:

• PhD in Pharmacology, University of Melbourne
• Bachelor of Science (Honours), University of Melbourne

Research Specializations and Academic Interests

Professor Kelly’s research primarily focuses on the mechanisms of fibrosis, particularly in the context of chronic kidney disease, diabetes, and cardiovascular disorders. His work emphasizes the development of novel therapeutic interventions to address fibrotic diseases, combining basic science with translational research to bring treatments from bench to bedside.

Career History and Appointments

Professor Kelly has held numerous prestigious positions throughout his career, reflecting his leadership in academia and industry. Key appointments include:

• Professor, Department of Medicine, University of Melbourne
• Director, Biomedical Research, St Vincent’s Hospital Melbourne
• Founder and CEO, Fibrotech Therapeutics (a biotechnology company focused on anti-fibrotic therapies, later acquired by Shire Pharmaceuticals in 2014)

Major Awards, Fellowships, and Honors

Professor Kelly has been recognized for his groundbreaking contributions to medical research with several prestigious awards, including:

• Australian Society for Medical Research (ASMR) Medal
• Victorian Premier’s Award for Health and Medical Research

Key Publications

Professor Kelly has authored numerous high-impact publications in peer-reviewed journals. Some of his notable works include:

• Kelly, D.J., et al. (2003). 'Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension.' Diabetes.
• Kelly, D.J., et al. (2005). 'A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR).' Kidney International.
• Kelly, D.J., et al. (2010). 'Anti-fibrotic therapies: From bench to bedside.' Journal of Molecular Medicine.

Influence and Impact on Academic Field

Professor Kelly’s research has had a profound impact on the understanding and treatment of fibrotic diseases, particularly in the context of diabetes and kidney disease. His leadership in founding Fibrotech Therapeutics and the subsequent development of anti-fibrotic drugs have positioned him as a pioneer in translating academic research into tangible clinical outcomes. His work continues to influence therapeutic strategies worldwide, contributing to advancements in patient care for chronic conditions.

Public Lectures, Committees, and Editorial Contributions

Professor Kelly is actively involved in the academic community, contributing through public lectures, editorial roles, and committee memberships. Notable contributions include:

• Regular keynote speaker at international conferences on fibrosis and chronic disease
• Member of editorial boards for leading journals in nephrology and pharmacology
• Advisor to national and international research funding bodies